{
  "id": "argo-pushes-gene-silencing-therapy-for-heart-risk-into-phase-2b",
  "title": "Argo pushes gene-silencing therapy for heart risk into Phase 2b",
  "summary": "First patient dosing signals growing confidence in siRNA therapies to tackle genetic cholesterol risk that accelerates cardiovascular disease. There is no bell-ringing moment when the first patient is dosed in a clinical trial. No applause. Just a confirmation that a long, uncertain chain of research has moved one step further. Still, this is exactly where [â€¦] The post Argo pushes gene-silencing therapy for heart risk into Phase 2b appeared first on Longevity.Technology.",
  "url": "https://longevity.technology/news/argo-pushes-gene-silencing-therapy-for-heart-risk-into-phase-2b/",
  "source": "Longevity.Technology",
  "author": "Kyle Umipig",
  "category": "news",
  "publishedAt": "2026-02-03T18:08:20.000Z",
  "fetchedAt": "2026-02-04T10:49:05.813Z",
  "relevanceScore": 0.6,
  "matchedKeywords": [
    "longevity",
    "clinical trial",
    "cardiovascular"
  ],
  "relatedProducts": [],
  "type": "web",
  "savedAt": "2026-02-04T10:49:05.855Z"
}